South Korea’s SK Biosciences to Manufacture Novavax’s COVID-19 Vaccine Antigen

Novavax has chosen South Korean drugmaker SK Biosciences to manufacture the antigen component of its COVID-19 vaccine NVX-CoV2373.

The two drugmakers have also signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to manufacture and supply the vaccine for South Korea and in other global markets.

SK Biosciences signed a deal with AstraZeneca last month to supply substances for AZ’s vaccine candidate.